IPO - Profile


Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$16.00 10,500,000 Positive High 40.46%

Offering Team

  • Legal counsel
  • Sidley Austin LLP
  • Auditors
  • Ernst & Young LLP

Deal Highlights

We are a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. We develop our product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Since our launch in 2019, we have developed a broad portfolio of novel antibody drug conjugate, or ADC, product candidates, and monoclonal antibody, or mAb, preclinical discovery programs that we are developing as monotherapies and in combination with other therapies. We take a holistic view of attacking the key drivers of tumor growth and progression within the tumor microenvironment, or TME, including targeting of tumor antigens and modulating the innate and adaptive immune response. The TME is an immunosuppressive environment consisting of cancer cells and stroma, which includes the blood vessels, immune cells, fibroblasts, signaling molecules, and the extracellular matrix that surrounds the tumor. The TME plays multiple roles in tumor formation, progression and metastasis as well as anti-tumor immune activity. We are developing our ADC and mAb product candidates to precisely target key modulators of the adaptive and innate immune system within the TME for difficult-to-treat solid and hematologic tumors.

Deal Tracker

IPO Dates

Filing 07 Oct, 2021

Offer 08 Oct, 2021

Look Ahead

Lock Up Expiry Apr 08, 2022

IPO Terms

Offer Price $16.00
Offer Size 10M

Market Sentiments

Stock Price